Atrial FibrillationNCT02699957
Left Atrial Appendage Occlusion Registry (LAAO Registry)
An observational study of Atrial Fibrillation, run by American College of Cardiology at 1 site in United States.
Trial summary
The Left Atrial Appendage Occlusion Registry (LAAO Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous and epicardial based left atrial appendage occlusion procedures to reduce the risk of stroke. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Left Atrial Appendage Occlusion
- Type of treatment
- Surgery or procedure
- How many people
- 3,000 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2015to Jan 2029
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All facilities performing percutaneous or epicardial left atrial appendage occlusion procedures.
Who may be able to join
- Adult patients, 18 years and older, undergoing percutaneous or epicardial left atrial appendage occlusion procedures
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
American College of Cardiology/National Cardiovascular Data Registry (NCDR)
Washington D.C., District of Columbia, 20037
NCDR Product Support, 1-800-257-4737, ncdr@acc.org
About this study
The Left Atrial Appendage Occlusion Registry (LAAO Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous and epicardial based left atrial appendage occlusion procedures to reduce the risk of stroke. Patient-level data will be submitted by participating hospitals on a quarterly basis to the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). The primary aims of the LAAO Registry are to optimize the outcomes and management of patients through the implementation of evidence-based guideline recommendations in clinical practice, facilitate efforts to improve the quality and safety for patients undergoing percutaneous and epicardial based left atrial appendage procedures, investigate novel quality improvement methods and provide risk-adjusted assessment of patients for comparison with nationwide NCDR data. The secondary purpose of the LAAO Registry is to serve as a rich source of clinical data to support assessments of short- and long-term safety, comparative and cost effectiveness research, and as a scalable data infrastructure for post market studies.
Read the detailed description
Hospitals join the Left Atrial Appendage Occlusion Registry (LAAO Registry) by agreeing to the terms of a specific contract that outlines the obligations of each party and the annual fees for participation. In addition, participating sites sign a Business Associate Agreement with the American College of Cardiology (ACC) as per the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The LAAO Registry dataset, comprised of approximately 300 data elements, was created by a panel of experts using available American College of Cardiology (ACC), Heart Rhythm Society (HRS), and Society for Cardiovascular Angiography and Interventions (SCAI) societal overview document guidance, data elements and definitions, previous trial data elements, and other evidentiary sources. Protected Health Information (PHI), such as social security number, is collected. The intent for collection of PHI is to allow for complete follow-up and tracking of the patient, to assist data managers in correcting data collection errors and improving data quality, for future registry interoperability and the potential for future generation of patient-level drill downs in Quality and Outcomes Reports (see section 11, Data Analysis and Statistical Considerations). Registry sites can opt out of transmitting direct identifiers to the National Cardiovascular Data Registry (NCDR), so inclusion of direct identifiers in the registry is at the discretion of the registry site. When using the NCDR web-based data collection tool, direct identifiers are entered but a partition between the data collection process and the data warehouse maintains the direct identifiers separate from the analysis datasets. The minimum level of PHI transmitted to the ACC when a participant opts out of submitting direct identifiers meets the definition of a Limited Dataset as such term is defined by the Health Insurance Portability and Accountability Act of 1996.
Data required for registry participation are collected retrospectively from existing medical records or concurrently in the normal course of treatment. The Societal Document and safety recommendations for left atrial appendage occlusion recommend additional testing and contact with the patient outside the hospital episode of care at 45 days, 6 months, 1 year and 2 years post-procedure. All registry data (in-hospital and follow-up) is captured by participating sites using an electronic data collection tool provided by the LAAO Registry or in the future the option will be available for collecting data using a certified software application that has been reviewed and certified as compliant with the transmissions specifications established by the ACC for the LAAO Registry.
Upon completion of a call for data window, participants prepare a data submission by exporting the data from their data collection mechanism and uploading their data to a secure https server at the ACC using approved encryption software with the highest encryption that is allowed.
In recognition of the importance of data quality to all of its registry products, and to ensure that data submitted to the NCDR are complete, consistent, and accurate, a Data Quality Program was formally established by the NCDR in 2004. Upon receipt of the LAAO Registry data submission, the ACC reviews the data electronically and reports back coding errors. Such electronic checks verify consistency and completeness and allow participants to have ample opportunity to submit data until it satisfies consistency and completion thresholds. The report produced from these data checks is called a Data Quality Report (DQR).
The DQR provides the participant with a confidential analysis of their data submission's completeness, and is used by the participant to help prioritize data cleaning efforts and to assess the necessity for re-submission.
Once the data meets the data quality thresholds, an Outcomes Report is produced. The Outcomes Report aggregates the participant's data and provides a comparison group (usually procedure volume based) and national comparison.
The NCDR understands the need to ensure the data submitted to the LAAO Registry is accurate and it has launched a national on-site and off-site audit program whereas a random set of participants participate in an on-site or off-site audit to confirm the data submitted to the registry is consistent with data in the medical record or source documentation.
- Conditions
- Atrial Fibrillation
- Being tested
- Left Atrial Appendage Occlusion
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Left Atrial Appendage OcclusionProcedure or surgery
Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
| Study group | Role | What they receive |
|---|---|---|
| Atrial Fibrillation | Those patients with the condition of atrial fibrillation. Receives: Procedure: Left Atrial Appendage Occlusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with a major complication
Proportion of patients experiencing any of the following events: Procedure aborted, conversion to open heart, hemorrhagic, ischemic or undetermined stroke, any effusion requiring drainage or surgery, device embolization, systemic embolism, or major bleeding event.
Measured: Assessed in hospital for any occurence from the start of procedure date and time until discharge date and time, assessed up to 24 months. Reported quarterly.
Secondary outcomes (1)
Proportion of patients who experience a stroke (ischemic or hemorrhagic), or systemic embolism or death after left atrial appendage occlusion during the follow up timeframes
Follow up metric for the proportion of patients who experience a stroke (ischemic or hemorrhagic), or systemic embolism or death after left atrial appendage occlusion.
Measured: Assessed at 45 day, 6 month, 1 year and 2 year follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2016 (estimated)
- Study startDec 2015
- Primary completionJan 2029 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- American College of Cardiology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paul Varosy, MD, Study chair, VA Eastern Colorado Health Care System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02699957
- Sponsor's protocol ID
- LAAO Registry
- Status last verified
- Jun 2026
- First submitted
- 9 Feb 2016
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Left Atrial Appendage Occlusion Registry (LAAO Registry)
- ClinicalTrials.gov ID
- NCT02699957
- Acronym / sponsor ID
- LAAO Registry
- Conditions
- Atrial Fibrillation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- American College of CardiologyUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- Jan 2029 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 7 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Left Atrial Appendage Occlusion Registry (LAAO Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous and epicardial based left atrial appendage occlusion procedures to reduce the risk of stroke. Patient-level data will be submitted by participating hospitals on a quarterly basis to the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). The primary aims of the LAAO Registry are to optimize the outcomes and management of patients through the implementation of evidence-based guideline recommendations in clinical practice, facilitate efforts to improve the quality and safety for patients undergoing percutaneous and epicardial based left atrial appendage procedures, investigate novel quality improvement methods and provide risk-adjusted assessment of patients for comparison with nationwide NCDR data. The secondary purpose of the LAAO Registry is to serve as a rich source of clinical data to support assessments of short- and long-term safety, comparative and cost effectiveness research, and as a scalable data infrastructure for post market studies.
Detailed description
Hospitals join the Left Atrial Appendage Occlusion Registry (LAAO Registry) by agreeing to the terms of a specific contract that outlines the obligations of each party and the annual fees for participation. In addition, participating sites sign a Business Associate Agreement with the American College of Cardiology (ACC) as per the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The LAAO Registry dataset, comprised of approximately 300 data elements, was created by a panel of experts using available American College of Cardiology (ACC), Heart Rhythm Society (HRS), and Society for Cardiovascular Angiography and Interventions (SCAI) societal overview document guidance, data elements and definitions, previous trial data elements, and other evidentiary sources. Protected Health Information (PHI), such as social security number, is collected. The intent for collection of PHI is to allow for complete follow-up and tracking of the patient, to assist data managers in correcting data collection errors and improving data quality, for future registry interoperability and the potential for future generation of patient-level drill downs in Quality and Outcomes Reports (see section 11, Data Analysis and Statistical Considerations). Registry sites can opt out of transmitting direct identifiers to the National Cardiovascular Data Registry (NCDR), so inclusion of direct identifiers in the registry is at the discretion of the registry site. When using the NCDR web-based data collection tool, direct identifiers are entered but a partition between the data collection process and the data warehouse maintains the direct identifiers separate from the analysis datasets. The minimum level of PHI transmitted to the ACC when a participant opts out of submitting direct identifiers meets the definition of a Limited Dataset as such term is defined by the Health Insurance Portability and Accountability Act of 1996.
Data required for registry participation are collected retrospectively from existing medical records or concurrently in the normal course of treatment. The Societal Document and safety recommendations for left atrial appendage occlusion recommend additional testing and contact with the patient outside the hospital episode of care at 45 days, 6 months, 1 year and 2 years post-procedure. All registry data (in-hospital and follow-up) is captured by participating sites using an electronic data collection tool provided by the LAAO Registry or in the future the option will be available for collecting data using a certified software application that has been reviewed and certified as compliant with the transmissions specifications established by the ACC for the LAAO Registry.
Upon completion of a call for data window, participants prepare a data submission by exporting the data from their data collection mechanism and uploading their data to a secure https server at the ACC using approved encryption software with the highest encryption that is allowed.
In recognition of the importance of data quality to all of its registry products, and to ensure that data submitted to the NCDR are complete, consistent, and accurate, a Data Quality Program was formally established by the NCDR in 2004. Upon receipt of the LAAO Registry data submission, the ACC reviews the data electronically and reports back coding errors. Such electronic checks verify consistency and completeness and allow participants to have ample opportunity to submit data until it satisfies consistency and completion thresholds. The report produced from these data checks is called a Data Quality Report (DQR).
The DQR provides the participant with a confidential analysis of their data submission's completeness, and is used by the participant to help prioritize data cleaning efforts and to assess the necessity for re-submission.
Once the data meets the data quality thresholds, an Outcomes Report is produced. The Outcomes Report aggregates the participant's data and provides a comparison group (usually procedure volume based) and national comparison.
The NCDR understands the need to ensure the data submitted to the LAAO Registry is accurate and it has launched a national on-site and off-site audit program whereas a random set of participants participate in an on-site or off-site audit to confirm the data submitted to the registry is consistent with data in the medical record or source documentation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Atrial Fibrillation | – | Procedure: Left Atrial Appendage OcclusionThose patients with the condition of atrial fibrillation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All facilities performing percutaneous or epicardial left atrial appendage occlusion procedures.
Key inclusion criteria (1 listed)
- Adult patients, 18 years and older, undergoing percutaneous or epicardial left atrial appendage occlusion procedures
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Left Atrial Appendage OcclusionPatients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion. | Procedure or surgery | Atrial Fibrillation |
Primary outcome
Proportion of patients with a major complication
Time frame: Assessed in hospital for any occurence from the start of procedure date and time until discharge date and time, assessed up to 24 months. Reported quarterly.
Proportion of patients experiencing any of the following events: Procedure aborted, conversion to open heart, hemorrhagic, ischemic or undetermined stroke, any effusion requiring drainage or surgery, device embolization, systemic embolism, or major bleeding event.
1 secondary outcome
Proportion of patients who experience a stroke (ischemic or hemorrhagic), or systemic embolism or death after left atrial appendage occlusion during the follow up timeframes
Time frame: Assessed at 45 day, 6 month, 1 year and 2 year follow up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- National Cardiovascular Data Registry (NCDR). Click this link for more information on the registry.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Paul Varosy, MD study chair
VA Eastern Colorado Health Care System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by American College of Cardiology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mark Fox, CHC, CHPC (202-375-6305, mfox@acc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with a major complication (time frame: Assessed in hospital for any occurence from the start of procedure date and time until discharge date and time, assessed up to 24 months. Reported quarterly.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.